Skip to main content
OpenTrials

Clinical trial condition

Chromophobe Renal Cell Carcinoma

Explore clinical trials studying Chromophobe Renal Cell Carcinoma. Study availability and eligibility vary by location and protocol.

13 public trials 3 recruiting studies
Refine in advanced search Browse all conditions

Chromophobe Renal Cell Carcinoma trial results

Recruiting

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

NCT03866382

Conditions
Adenocarcinoma, Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma, +71 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
View all 581 locations
View Trial Details
Recruiting

A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

NCT06805825

Conditions
Adenocarcinoma, Adenoid Cystic Carcinoma, Albinism, +58 more
Locations
  • University of Michigan Hospitals Ann Arbor, Michigan, United States
  • Case Comprehensive Cancer Center Cleveland, Ohio, United States
  • Oregon Health & Science University Portland, Oregon, United States
  • The University of Texas MD Anderson Cancer Center Houston, Texas, United States
View Trial Details
Active, not recruiting

Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study

NCT04071223

Conditions
Adenocarcinoma, Advanced Renal Cell Carcinoma, Carcinoma, +22 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • University of California Davis Comprehensive Cancer Center Sacramento, California, United States
  • Rush MD Anderson Cancer Center Chicago, Illinois, United States
View all 47 locations
View Trial Details
Active, not recruiting

Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC

NCT04413123

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +21 more
Locations
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • Brigham & Woman's Hospital Boston, Massachusetts, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • UT Southwestern Medical Dallas, Texas, United States
View Trial Details
Active, not recruiting

A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma

NCT03635892

Conditions
Adenocarcinoma, Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma, Carcinoma, +20 more
Locations
  • Memorial Sloan Kettering Basking Ridge Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen Montvale, New Jersey, United States
  • Memorial Sloan Kettering Commack Commack, New York, United States
View Trial Details

Related conditions